Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.
BRAF inhibitor
Low grade serous ovarian cancer
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
18
03
2024
revised:
05
05
2024
accepted:
06
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and molecular characteristics as well as surgical considerations and ongoing investigations in LGSOC.
Identifiants
pubmed: 38779189
doi: 10.1016/j.gore.2024.101412
pii: S2352-5789(24)00091-2
pmc: PMC11109349
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
101412Informations de copyright
© 2024 The Authors. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.